Revolution Medicines has reported tumour shrinkage or disappearance in 60.7% of 61 patients given daraxonrasib plus chemotherapy as their first treatment for metastatic pancreatic cancer. The updated early-phase results included complete responses in 8.2% of patients, meaning their tumours were no longer detectable on scans. Source Source
The phase 1/2 cohort had no chemotherapy-only comparison group, so it cannot establish that adding daraxonrasib works better than chemotherapy alone. Nor do scan-undetectable tumours establish a cure. Source Source
The company announced the RMC-GI-102 study update on November 19, 2026, with results scheduled for presentation on November 20 at the EORTC-NCI-AACR Symposium in Barcelona. The analysis used a September 28 data cutoff, with median follow-up of 18.3 months. Revolution Medicines sponsored the study. Source Source
Survival estimates
The company reported median progression-free survival of 12.8 months, a distinct measure from overall survival. Estimated survival at one year was 76.6%, or roughly three in four patients. The reported 95% confidence interval was 63.7%–85.4%, reflecting uncertainty around that estimate. Source
Cancer Research UK’s Dr Sam Godfrey told the BBC: “Cancer can come back and even if scans show there is no sign of it, you don't necessarily know you are cancer-free until more time has passed.” Source
A daily pill, not a replacement for chemotherapy
Daraxonrasib is designed to inhibit active RAS, a protein involved in signals that drive cancer growth. According to the conference announcement, more than 90% of pancreatic cancers have a RAS mutation. Source
Patients in this cohort took daraxonrasib orally once a day alongside two intravenous chemotherapy drugs, gemcitabine and nab-paclitaxel. Source
The conference announcement listed common adverse effects including rash, diarrhoea, fatigue and reductions in blood-cell counts. It reported that 5% of patients discontinued treatment because of side effects attributed to daraxonrasib.
Comments